|

R-DXD Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: DS-6000a, MK-5909, Raludotatug deruxtecan

Pipeline

Phase 2: 1Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Merck Sharp & Dohme LLC2
  • Daiichi Sankyo1

Indications

  • Cancer3
  • Lung Cancer2
  • Small Cell Lung Carcinoma1
  • Solid Cancer1
  • Lung Neoplasm1

Anchorage, Alaska1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alaska Women's Cancer Care

Phase 2/3

Gilbert, Arizona1 trial

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Banner MD Anderson Cancer Center ( Site 0152)

Phase 1/2

Lexington, Kentucky1 trial

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.